Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MRKR

MRKR - Marker Therapeutics Inc Stock Price, Fair Value and News

$1.62-0.18 (-10.00%)
Market Closed

29/100

MRKR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

29/100

MRKR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.68

Target 3M

$1.96

Target 6M

$1.82

MRKR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRKR Price Action

Last 7 days

-26.0%

Last 30 days

6.6%

Last 90 days

63.6%

Trailing 12 Months

-22.5%

MRKR RSI Chart

MRKR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRKR Valuation

Market Cap

27.0M

Price/Earnings (Trailing)

-1.89

Price/Sales (Trailing)

5.75

EV/EBITDA

0.53

Price/Free Cashflow

-1.82

MRKR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.68

Target 3M

$1.96

Target 6M

$1.82

MRKR Fundamentals

MRKR Revenue

Revenue (TTM)

4.7M

Rev. Growth (Yr)

-35.99%

Rev. Growth (Qtr)

43.17%

MRKR Earnings

Earnings (TTM)

-14.3M

Earnings Growth (Yr)

13.41%

Earnings Growth (Qtr)

50.23%

MRKR Profitability

EBT Margin

-227.51%

Return on Equity

-77.75%

Return on Assets

-65.78%

Free Cashflow Yield

-54.86%

MRKR Investor Care

Shares Dilution (1Y)

86.85%

Diluted EPS (TTM)

-1.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20255.7M5.4M4.7M0
20243.3M3.7M5.4M6.6M
20233.8M3.8M3.0M3.3M
20221.8M2.4M2.9M3.5M
20210001.2M
2020266.7K333.4K400.1K466.8K
2019000200.0K
20180389.1K389.1K206.0K
201700414.3K183.1K
20160375.4K359.8K344.2K
2012422.2K406.6K00
2011928.8K683.3K0437.8K
20100001.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Marker Therapeutics Inc

MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.
 CEO
 WEBSITEmarkertherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES67

Marker Therapeutics Inc Frequently Asked Questions

MRKR is the stock ticker symbol of Marker Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Marker Therapeutics Inc is 27.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MRKR's fair value in chart for subscribers.

The fair value guage provides a quick view whether MRKR is over valued or under valued. Whether Marker Therapeutics Inc is cheap or expensive depends on the assumptions which impact Marker Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRKR.

As of Wed Jan 28 2026, MRKR's PE ratio (Price to Earnings) is -1.89 and Price to Sales (PS) ratio is 5.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRKR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Marker Therapeutics Inc has provided -0.315 (multiply by 100 for percentage) rate of return.